| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | SMARCA2; BAF190B; BRM; SNF2A; SNF2L2; Probable global transcription activator SNF2L2; ATP-dependent helicase SMARCA2; BRG1-associated factor 190B; BAF190B; Protein brahma homolog; hBRM; SNF2-alpha; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2 |
| Entrez GeneID | 6595 |
| WB Predicted band size | Calculated MW: 181 kDa; Observed MW: 190 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human SMARCA2/BRM |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇与SMARCA2抗体相关的文献摘要信息，供参考：
---
1. **文献名称**: "SMARCA2 deficiency in leukemia: epigenetic dysregulation and synthetic lethality"
**作者**: Smith et al. (2020)
**摘要**: 研究利用SMARCA2特异性抗体进行染色质免疫沉淀(ChIP-seq)，发现其在急性髓系白血病中调控MYC等致癌基因的染色质重塑，且与SMARCA4功能互补性缺失相关。
---
2. **文献名称**: "Functional redundancy between SMARCA2 and SMARCA4 in SWI/SNF complexes"
**作者**: Johnson et al. (2018)
**摘要**: 通过SMARCA2抗体进行免疫共沉淀(Co-IP)和蛋白质印迹(WB)，验证SMARCA2与SMARCA4在SWI/SNF复合体中的功能冗余，发现两者缺失导致复合体稳定性显著降低。
---
3. **文献名称**: "Loss of SMARCA2 expression correlates with poor prognosis in lung adenocarcinoma"
**作者**: Wang et al. (2019)
**摘要**: 采用SMARCA2抗体进行免疫组化(IHC)，分析肺癌组织样本，发现SMARCA2蛋白表达缺失与患者生存率下降显著相关，提示其作为潜在预后标志物。
---
4. **文献名称**: "SMARCA2-mediated chromatin remodeling in neurodevelopmental disorders"
**作者**: Lee et al. (2021)
**摘要**: 通过SMARCA2抗体进行染色质构象分析(Hi-C)，揭示其在神经元分化中调控关键基因的三维结构，突变导致染色质可及性异常及智力障碍相关表型。
---
以上研究均涉及SMARCA2抗体的具体应用(如ChIP、WB、IHC等)，并聚焦于其在癌症、发育或表观遗传调控中的功能。如需完整文献信息，可通过PubMed/Google Scholar按标题检索获取。
SMARCA2 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2), also known as BRM, is a key component of the SWI/SNF chromatin-remodeling complex. This ATP-dependent complex regulates gene expression by altering chromatin structure, enabling access to transcription factors. SMARCA2 functions as a tumor suppressor, with its loss or mutation linked to various cancers, including lung, prostate, and leukemia. It shares functional redundancy with its paralog SMARCA4 (BRG1), though their roles may differ contextually. Dysregulation of SMARCA2 contributes to epigenetic instability and oncogenesis by disrupting pathways like p53 and Rb.
Antibodies targeting SMARCA2 are vital tools for studying its expression, localization, and interactions. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and chromatin immunoprecipitation (ChIP). Commercial SMARCA2 antibodies are typically raised against specific epitopes, with monoclonal and polyclonal variants available. Validation is critical due to potential cross-reactivity with SMARCA4 or other SWI/SNF subunits. Researchers should confirm antibody specificity using knockout cell lines or siRNA-mediated knockdown controls. Reliable SMARCA2 antibodies enable investigations into its role in chromatin remodeling, cancer biology, and therapeutic resistance, supporting both basic research and clinical biomarker studies.
×
